| Autor: |
Al-Azawi, Ahmed, Hneua, Riyadh Abd-Alrasool, Hameed, Rana Majeed, Hassan, Duha Maithem |
| Předmět: |
|
| Zdroj: |
Journal of Contemporary Medical Sciences; May/Jun2023, Vol. 9 Issue 3, p197-200, 4p |
| Abstrakt: |
Objectives: In this trial, it has been investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer in compares to patients who received only Herceptin. Methods: After surgery and central HER2-positive confirmation, about randomly 220 patients assigned with high-risk HER2-positive, operable breast cancer to received Anthracycline based chemotherapy 3 cycles fallowed by Taxotere 3 + either pertuzumab+hercetin 3 or standard adjuvant Herceptin alone, 17 cycles in 1 year. The patients were followed up for 3 years. Results: Results were indicated that about 50% of the patients who were randomly assigned to arm A received pertuzumab + Herceptin 3 cycles every 3 weeks (110 patients) and arm B 50% (110 patients) received Herceptin alone 17 cycles every 3 weeks. Disease recurrence occurred in 12 patients (10.9 %) in the pertuzumab group and 8 patients (7.2%) in the arm B group (hazard ratio, 0.81; 95% confidence interval [CI], 0.66 to 1.00; P = 0.045). The estimates of the 3-year rates of invasive-disease-free survival were 89% in the pertuzumab + herceptin group and 93% in the herceptin group. Heart failure, cardiac death, and cardiac dysfunction were infrequent in both treatment groups. Diarrhea of grade 3 or higher occurred almost exclusively during chemotherapy and it was more frequent with pertuzumab than with group B (7.9% vs. 2.8%). Conclusions: The study showed that pertuzumab + Trastuzumab adjuvant in 3 cycles worse rates of invasive-disease-free survival among patients with HER2-positive, operable breast cancer in compares with classical trastuzumab alone in 17 cycles. Diarrhea was more common with pertuzumab than with classical Trastuzumab therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
